# Clopidogrel Monotherapy in Patients With High Bleeding Risk

> **NCT05223335** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 98 (actual)

## Conditions studied

- Bleeding Complications

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Prasugrel
- **DRUG:** Tricagrelor

## Key facts

- **NCT ID:** NCT05223335
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-29
- **Primary completion:** 2023-03-16
- **Final completion:** 2023-03-16
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223335, "Clopidogrel Monotherapy in Patients With High Bleeding Risk". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05223335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*